Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Neuropeptides is Scopus-indexed (Q2, CiteScore 5), WoS SCIE. It is covered by India's One Nation One Subscription scheme for reading access. Published by Churchill Livingstone.
Checked against the index lists dated .
ISSN 0143-4179Verify ISSN ↗1532-2785Verify ISSN ↗
Publisher: Churchill Livingstone
Cost to publish: About US$3,530 to publish open access (publisher list price, via OpenAlex) — subscription publishing may be free
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Neurology | 71 / 201 | 64th | Q2 |
| Endocrine and Autonomic Systems | 11 / 23 | 54th | Q2 |
| Endocrinology | 64 / 132 | 51st | Q2 |
| Cellular and Molecular Neuroscience | 61 / 102 | 40th | Q3 |
Not listed in: DOAJ, ABDC, ABS / AJG, FT50, UT Dallas, ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 1980–present, best quartile Q2, CiteScore 5.
Neuropeptides is Q2 in Neurology (rank 71 of 201), Q2 in Endocrine and Autonomic Systems (rank 11 of 23) and Q2 in Endocrinology (rank 64 of 132), by CiteScore 2025. It is ranked in 4 subject areas in all.
Neuropeptides is indexed in the Science Citation Index Expanded, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 5, which places it in quartile Q2 at the 64th percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 0.786, quartile Q2, with an H-index of 83.
The publisher lists an article processing charge of about US$3,530 for open access (source: OpenAlex). Many journals also publish by the subscription route at no cost to the author, so confirm on the journal's own website.
Neuropeptides is published by Churchill Livingstone. Its print ISSN is 0143-4179 and its online ISSN is 1532-2785.
Yes. It is part of the One Nation One Subscription (ONOS) national subscription, so readers at participating Indian institutions get its full text. ONOS does not cover its article processing charge.
Yes — indexed in the Science Citation Index Expanded.
No — it is not registered as an open-access journal in DOAJ or Scopus.
Neuropeptides has an h-index of 105 and a 2-year mean of 3.1 citations per paper (OpenAlex). Its Scopus CiteScore is 5, quartile Q2. On 2-year citations it ranks #49 of 201 Scopus journals in Neurology.
Neuropeptides published 53 papers in 2025; its busiest recent year was 2017 with 144. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 96 research articles (2024–2026), authors are most often from China (32.3%), India (16%) and United States (12.2%).
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. 7 retracted papers are recorded (1.6 per 1,000 papers). The Problematic Paper Screener flags 1 of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.